Pediatric Updates on Transplant Associated-Thrombotic Microangiopathy (TA-TMA)

<p>KaShena L. Kennedy, PharmD (Twitter: <a href='https://twitter.com/KaShenaKennedy'>@KaShenaKennedy</a>) reviews and identifies the pathophysiology, clinical manifestations, and diagnostic criteria for TA-TMA in pediatric patients, differentiates risk factors associated with TA-TMA and discusses prophylactic treatment in pediatric patients and explores treatment and emerging therapy options of TA-TMA in pediatric patients.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>